Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neuraxis, Inc. (NRXS : AMEX)

• Company Description    NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis, Inc. is based in CARMEL, Ind. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $7.38 Daily Weekly Monthly 20 Day Moving Average: 193,519 shares Shares Outstanding: 12.38 (millions) Market Capitalization: $91.39 (millions) Beta: 1.50 52 Week High: $9.33 52 Week Low: $2.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.94% -5.78% 12 Week 29.70% 19.90% Year To Date 62.55% 50.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11611 N. Meridian Street Suite 330 - Carmel,IN 46032 USA ph: 812-689-0791 fax: - ir@neuraxis.com https://neuraxis.com

• General Corporate Information    Officers Brian Carrico - President; Chief Executive Officer and Director Bradley Mitch Watkins - Director and Chairman of the Board Timothy Henrichs - Chief Financial Officer Adrian Miranda - Senior Vice President of Science and Technology Beth Keyser - Director Peer Information Neuraxis, Inc. (HLIS) Neuraxis, Inc. (AZTA) Neuraxis, Inc. (APYI) Neuraxis, Inc. (RNVA) Neuraxis, Inc. (HMSY) Neuraxis, Inc. (LRSI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: 64134X201 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 12.38 Most Recent Split Date: (:1) Beta: 1.50 Market Capitalization: $91.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 15.91 Price/Cash Flow: - Price / Sales: 21.35 EPS Growth vs. Year Ago Period: 41.94% vs. Previous Quarter: -5.88% Sales Growth vs. Year Ago Period: 79.46% vs. Previous Quarter: 66.12% ROE 03/31/26 - -185.91 12/31/25 - -314.92 09/30/25 - -350.51 ROA 03/31/26 - -103.99 12/31/25 - -143.76 09/30/25 - -150.16 Current Ratio 03/31/26 - 2.89 12/31/25 - 2.05 09/30/25 - 1.59 Quick Ratio 03/31/26 - 2.81 12/31/25 - 1.96 09/30/25 - 1.55 Operating Margin 03/31/26 - -170.12 12/31/25 - -224.54 09/30/25 - -230.61 Net Margin 03/31/26 - -170.12 12/31/25 - -224.54 09/30/25 - -230.61 Pre-Tax Margin 03/31/26 - -170.12 12/31/25 - -218.58 09/30/25 - -224.27 Book Value 03/31/26 - 0.46 12/31/25 - 0.32 09/30/25 - 0.23 Inventory Turnover 03/31/26 - 3.48 12/31/25 - 4.20 09/30/25 - 6.65 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©